BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18004253)

  • 21. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy.
    Kouloubinis A; Kaklamanis L; Ziras N; Sofroniadou S; Makaritsis K; Adamopoulos S; Revela I; Athanasiou A; Mavroudis D; Georgoulias V
    Int J Cardiol; 2007 Nov; 122(3):195-201. PubMed ID: 17289172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea.
    Bayes-Genis A; Lloyd-Jones DM; van Kimmenade RR; Lainchbury JG; Richards AM; Ordoñez-Llanos J; Santaló M; Pinto YM; Januzzi JL
    Arch Intern Med; 2007 Feb; 167(4):400-7. PubMed ID: 17325303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke.
    Iltumur K; Yavavli A; Apak I; Ariturk Z; Toprak N
    Am Heart J; 2006 May; 151(5):1115-22. PubMed ID: 16644347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Personal experience with determination of NT-proBNP in clinical practice].
    Stejskal D; Oral I; Lacnák B; Juráková R; Horalík D; Adamovská S; Prosková J; Hrabovská I; Ozanová G
    Vnitr Lek; 2003 Feb; 49(2):121-6. PubMed ID: 12728579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure.
    Dieplinger B; Gegenhuber A; Struck J; Poelz W; Langsteger W; Haltmayer M; Mueller T
    Clin Chim Acta; 2009 Feb; 400(1-2):91-6. PubMed ID: 19000665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.
    Weber M; Bazzino O; Navarro Estrada JL; Fuselli JJ; Botto F; Perez de Arenaza D; Möllmann H; Nef HN; Elsässer A; Hamm CW
    J Am Coll Cardiol; 2008 Mar; 51(12):1188-95. PubMed ID: 18355657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia.
    Horacek JM; Tichy M; Jebavy L; Pudil R; Ulrychova M; Maly J
    Exp Oncol; 2008 Jun; 30(2):157-9. PubMed ID: 18566582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-terminal pro-brain natriuretic peptide as a potential non-invasive marker of cardiac transplantation rejection.
    Avello N; Molina BD; Llorente E; Bernardo MJ; Prieto B; Alvarez FV
    Ann Clin Biochem; 2007 Mar; 44(Pt 2):182-8. PubMed ID: 17362585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevation of myeloperoxidase in conjunction with cardiac-specific markers after marathon running.
    Melanson SE; Green SM; Wood MJ; Neilan TG; Lewandrowski EL
    Am J Clin Pathol; 2006 Dec; 126(6):888-93. PubMed ID: 17074690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline natriuretic peptide levels in relation to myocardial ischemia, troponin T release and heart rate variability in patients undergoing major vascular surgery.
    Feringa HH; Vidakovic R; Karagiannis SE; de Jonge R; Lindemans J; Goei D; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2007 Dec; 18(8):645-51. PubMed ID: 18004116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.
    Björklund E; Jernberg T; Johanson P; Venge P; Dellborg M; Wallentin L; Lindahl B;
    Heart; 2006 Jun; 92(6):735-40. PubMed ID: 16251228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.
    Roziakova L; Bojtarova E; Mistrik M; Dubrava J; Gergel J; Lenkova N; Mladosievicova B
    J Exp Clin Cancer Res; 2012 Feb; 31(1):13. PubMed ID: 22321767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes.
    Galvani M; Ottani F; Oltrona L; Ardissino D; Gensini GF; Maggioni AP; Mannucci PM; Mininni N; Prando MD; Tubaro M; Vernocchi A; Vecchio C;
    Circulation; 2004 Jul; 110(2):128-34. PubMed ID: 15197143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema.
    Behnes M; Brueckmann M; Ahmad-Nejad P; Lang S; Wolpert C; Elmas E; Kaelsch T; Gruettner J; Weiss C; Borggrefe M; Neumaier M
    Int J Cardiol; 2009 Jun; 135(2):165-74. PubMed ID: 18603317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.
    Krauser DG; Lloyd-Jones DM; Chae CU; Cameron R; Anwaruddin S; Baggish AL; Chen A; Tung R; Januzzi JL
    Am Heart J; 2005 Apr; 149(4):744-50. PubMed ID: 15990762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study.
    Jacobs LH; van de Kerkhof JJ; Mingels AM; Passos VL; Kleijnen VW; Mazairac AH; van der Sande FM; Wodzig WK; Konings CJ; Leunissen KM; van Dieijen-Visser MP; Kooman JP
    Nephrol Dial Transplant; 2010 Jan; 25(1):243-8. PubMed ID: 19692417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
    David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
    Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.